Navigation Links
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
Date:1/4/2011

h the introduction of new medicines.  Anadys has initiated a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) expectations regarding the timing for commencing patient dosing in the ANA598 Phase IIb study; (ii) the goal of establishing safety and efficacy in a greater number of patients, including those who have failed prior HCV treatment; (iii) the hope to position ANA598 as a highly attractive HCV agent ready for Phase III development; (iv) the scheduled trial design for the Phase IIb study; and (v) Anadys' expectations regarding the timing of receipt of data from the study.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficultie
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
6. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
7. Anadys Retains Lazard as Strategic Advisor
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Louisiana (PRWEB) September 16, 2014 New ... an amazing new product for corporate wellness programs and ... Kit. , “In the past, cholesterol screening was ... large amount of products, variable SKUs and storage space ... “With our Universal Cholesterol Screening Kits, it’s easy: one ...
(Date:9/16/2014)... Pass, OR (PRWEB) September 16, 2014 ... is experiencing a major extended drought crisis that in ... survival. Grigg praises the many individuals who are dedicated ... fresh water policy solutions overlook large portion of the ... new, possibly worse crises.     , Grigg explained his, “total ...
(Date:9/16/2014)... 2014 Oxnard dentist and ... Dental Art Institute in Oxnard and Woodland Hills, Calif., ... weekend. , Dr. Jivraj, an expert in teeth restoration ... in his presentation “Clinical and Laboratory Aspects of ... p.m. Saturday, Sept. 20, at the Empire Landmark Hotel ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
Breaking Medicine News(10 mins):Health News:New Line Medical Launches Universal Cholesterol Screening Kits 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3
... the monotone of an instructor or insufficient rest the night ... trouble staying awake in class. Researchers have now found a ... awake during class, and it doesn't have anything to do ... alertness by applying acupressure at stimulation points to keep themselves ...
... Being one of the fastest progressing and spreading diseases of ... going on in this direction and a new study states ... to osteoarthritis. ,The study was conducted at ... the ability of an extract of pomegranate fruit against Interleukin-1b ...
... Vioxx, pain killer which was found to cause the death ... Merck Pharma the manufacturers of Vioxx were asked by the ... to Mrs. Ernst. Over 5 years, about 20 million people ... September 2004, after a clinical trial found irrefutable evidence that ...
... obstetricians urge their pregnant patients to exercise regularly, when ... ,The researcher from Saint Louis University School of ... September issue of a publication for obstetricians and gynecologists. ... exercise in women with healthy pregnancies results in no ...
... tiny delivery vehicles that can carry anticancer therapeutic ... genetic material constructed through nanotechnology, offering a potential ... This emerging branch of science is called nanomedicine. ... are assembled from three short pieces of ribonucleic ...
... through the scientific circles that soft trans fat-free margarines in ... disease. ,The study is one of the many aimed ... risk for coronary heart disease (CHD) was more closely associated ... fat-free margarines made from soybean and canola oil)(1). In fact, ...
Cached Medicine News:Health News:Pomegranate Juice Is Helpful In Arresting Osteoarthritis 2Health News:RNA Nanotechnology To Rescue Cancer Patients In Future 2Health News:PUFA Good For Heart: Gets The Scientific Seal 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: